CYP2D6 Inhibitors Drugs that inhibit CYP2D6 activity are likely to increase the plasma concentrations of certain medications, and, in some cases, adverse outcomes will occur (see Table 3 below right for a list of known inhibitors). Some drugs, such as fluoxetine, paroxetine, and quinidine, are...
Selected inducers, inhibitors and substrates of CYP2D6[6] Substrates Inhibitors Inducers Often mentioned: [7] beta-blockers metoprolol carvedilol timolol Class I antiarrhythmics flecainide lidocaine propafenone encainide mexiletine All tricyclic antidepressants, e.g. imipramine amitriptyline etc. ...
CYP2D6 Inhibitors Concurrent use of CYP2D6 inhibitor medications may decrease or prevent the conversion of opioid medications to morphine. Therefore, we excluded participants who were prescribed a medication that was a strong or moder- ately strong inhibitor of CYP2D6.24 The list of inhibitors ...
Prescribing information does not list CYP2D6 status as a contraindication for tamoxifen. Pharmacological supression of hot flashes by comedication with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) must be avoided because such patients will become functional Poor metabolizers with lower endoxifen ...
Strong inhibitors of CYP2D6 decrease the enzyme activity to near zero, causing individuals who display normal or intermediate genotypes to mimic a poor metabolizer [9]. Commonly prescribed medications that are known strong inhibitors of the CYP2D6 enzyme include bupropion, fluoxetine, paroxetine, ...
of the two most potent metabolites of tamoxifen: endoxifen and 4-OH tamoxifen (Figure 1).2 The metabolic activity of CYP2D6 is known to be influenced by the individual's genotype and by environmental factors (e.g., the ingestion of CYD2D6 inhibitors, which are commonly pre- scribed)....
In contrast, endoxifen plasma concentrations are up to 10- fold higher than 4HT, exhibiting substantial variability.17,22,30 Patients with low CYP2D6 enzyme activity, as a result of CYP2D6 genetic polymorphisms or the coadministration of strong CYP2D6 inhibitors, exhibit significantly lower ...
This is exemplified by the selective serotonin reuptake inhibitors33 for young children, with poorly defined starting dose, compounded by parent comfort level and provider experience.34 Dose adjustments are based largely on parent and teacher impressions of medication tolerance and effect, requiring 4 ...
Keywords: CYP2D6, Non-small cell lung cancer, Gefitinib, Erlotinib, Adverse events Background Compared to cytotoxic agents, gefitinib and erlotinib are orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) that prolong survival, have few hematological adverse events,...
A list of inhibitors that was considered for this study is shown in Table S3. Because most of these prescriptions are intended to be taken long term, we considered persons exposed to a CYP2D6 inhibitor if the prescription occurred within 1 year prior to the opioid prescription. Analyses The ...